STUART, Fla.–(BUSINESS WIRE)–Stuart Therapeutics Inc., a late-stage biopharmaceutical company developing a new class of therapeutics designed to treat eye diseases by repairing helical collagen, today announced it has submitted an investigational new drug application amendment to the U.S. Food and Drug Administration to study its lead candidate, ST-100 (vezocolmitide), in corneal wound healing. The planned proof-of-concept study would mark ST-100’s first expansion beyond dry eye disease and co

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.